ES2053676T3 - Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. - Google Patents

Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.

Info

Publication number
ES2053676T3
ES2053676T3 ES88117833T ES88117833T ES2053676T3 ES 2053676 T3 ES2053676 T3 ES 2053676T3 ES 88117833 T ES88117833 T ES 88117833T ES 88117833 T ES88117833 T ES 88117833T ES 2053676 T3 ES2053676 T3 ES 2053676T3
Authority
ES
Spain
Prior art keywords
high ionic
recombinants
formulation
plasma proteins
ionic force
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88117833T
Other languages
English (en)
Spanish (es)
Inventor
Ted C K Lee
Michael E Hrinda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2053676(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of ES2053676T3 publication Critical patent/ES2053676T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
ES88117833T 1987-10-29 1988-10-26 Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. Expired - Lifetime ES2053676T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29

Publications (1)

Publication Number Publication Date
ES2053676T3 true ES2053676T3 (es) 1994-08-01

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88117833T Expired - Lifetime ES2053676T3 (es) 1987-10-29 1988-10-26 Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.

Country Status (8)

Country Link
EP (1) EP0314095B1 (OSRAM)
JP (1) JP2544968B2 (OSRAM)
AT (1) ATE83155T1 (OSRAM)
AU (1) AU622133B2 (OSRAM)
CA (1) CA1329760C (OSRAM)
DE (1) DE3876600T2 (OSRAM)
ES (1) ES2053676T3 (OSRAM)
GR (1) GR3006506T3 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148165T1 (de) * 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6162629A (en) 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1561469A1 (en) * 1997-04-28 2005-08-10 Eli Lilly & Company Activated Protein C Formulations
ATE220558T1 (de) * 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
PL203893B1 (pl) * 1999-02-22 2009-11-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
AU2003251906B2 (en) * 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
KR101578561B1 (ko) * 2007-04-26 2015-12-17 바이엘 헬스케어 엘엘씨 냉동 저장을 위한, 재조합 단백질의 액상 용액의 안정화
AU2009313325B2 (en) 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations
CN103282045A (zh) * 2010-12-16 2013-09-04 诺沃—诺迪斯克有限公司 因子viii水溶液
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
WO2014026954A1 (en) * 2012-08-13 2014-02-20 Novo Nordisk A/S Liquid factor viii formulations
KR20180079384A (ko) * 2015-11-05 2018-07-10 노보 노르디스크 에이/에스 Fviii 제제
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
AU2452088A (en) 1989-05-04
CA1329760C (en) 1994-05-24
AU622133B2 (en) 1992-04-02
DE3876600T2 (de) 1993-04-15
GR3006506T3 (OSRAM) 1993-06-30
EP0314095A1 (en) 1989-05-03
JPH01149733A (ja) 1989-06-12
ATE83155T1 (de) 1992-12-15
DE3876600D1 (de) 1993-01-21
JP2544968B2 (ja) 1996-10-16
EP0314095B1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
ES2053676T3 (es) Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
DK562888A (da) Aminomethyl-oxooxazolidinyl-cycloalkylbenzenderivater, fremstilling deraf, praeparater indeholdende disse og deres anvendelse som antibakterielle midler
HUP0100284A2 (hu) Aktivált protein C készítmények
PT758248E (pt) Formulacoes para o factor ix
AU573523B2 (en) Functional human urokinase proteins
FI91160B (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
GR1001040B (el) Ενζυμο σταθεροποιητικη συνθεση και συνθεσεις δομικου απορρυπαντικου που περιεχουν σταθεροποιητικο ενζυμο.
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
HUT47436A (en) Process for stabilizing pharmaceutically active proteines in pharmaceutical compositions
AU634280B2 (en) Anticoagulant peptides
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
AU4588089A (en) Anticoagulant peptides
AU1174588A (en) Anticonvulsant agents
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
AU2323992A (en) Sequence for stabilizing proteins in bacteria protein stabilization sequence
AU580890B2 (en) P-acylaminobenzamides
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
DE69907727D1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
SE9604439D0 (sv) New receptor
GR880100401A (el) 8α-ακυλαμινεργολινη,παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 314095

Country of ref document: ES